MaxCyte, Inc. Tech Stack

Cell therapy manufacturing platform based on flow electroporation technology

Biotechnology Rockville, Maryland 51–200 employees Founded 1999 Public Company

MaxCyte manufactures instruments and disposables for cell therapy production using proprietary flow electroporation technology. The tech stack—Python, R, GATK, Nextflow, AWS, Docker—reflects a bioinformatics and computational biology focus rather than pure manufacturing software, suggesting internal process optimization and possibly cell characterization workflows. Active hiring spans engineering, sales, operations, and research with a skew toward senior and director roles, while projects reveal dual priorities: internal systems modernization and field-facing sales enablement (CRM adoption, territory design, distributor management).

Tech Stack 11 technologies

Core StackPython GitHub AWS Docker Linux GATK R Nextflow GCP AWS Batch CMMS

What MaxCyte, Inc. Is Building

◆Challenges

Process transformation
Systems modernization
Scalable growth
Process improvements in transfection workflow
Improving viability and editing efficiency
Improving forecast accuracy
Sales productivity
Scaling teams
Expanding market penetration
Improving pipeline accuracy

▲Active Projects

Building renovations
Disaster continuity planning
Process transformation
Systems modernization
Pre-sales high-potential project identification
Scale-up optimization of transfection workflows
Develop sops and best-practice resources
Regional business planning and territory design
Crm adoption and funnel management
Distributor strategy and performance management

Hiring Activity

Accelerating9 roles · 6 in 30d

Department

Engineering

Sales

Finance

Operations

Ops

Research

Seniority

Senior

Director

Manager

Mid

Company intelligence

Find more companies like MaxCyte, Inc. by tech stack, pain points and active projects

Get started free

About MaxCyte, Inc.

MaxCyte is a public biotechnology company based in Rockville, Maryland, founded in 1999. The company provides the ExPERT platform—a family of four instruments (ATx, STx, GTx, VLx) plus processing assemblies and software—designed to support cell and gene therapy manufacturing from discovery through commercialization. Partners use the platform for transfection, immunotherapy, cancer treatment, and vaccine development. MaxCyte operates globally with a presence in multiple regions, though current hiring is concentrated in the United States. The company positions itself as a technical partner, offering not only hardware and disposables but also regulatory guidance and process optimization support to de-risk customers' paths to clinical deployment.

HeadquartersRockville, Maryland

Company Size51–200 employees

Founded1999

Hiring MarketsUnited States

Frequently Asked Questions

What is MaxCyte's core technology?

MaxCyte's ExPERT platform is based on Flow Electroporation® technology and includes four instruments (ATx, STx, GTx, VLx), proprietary processing assemblies, and software protocols for cell and gene therapy manufacturing.

What tech stack does MaxCyte use?

MaxCyte uses Python, R, GATK, Nextflow, AWS, GCP, Docker, AWS Batch, Linux, and CMMS. This computational biology and bioinformatics stack suggests internal workflow optimization and cell characterization capabilities.